Volition adds a cat cancer test to its Fujifilm deal
Volition widened its Fujifilm Vet Systems agreement in Japan to cover the Nu.Q Vet Feline Test, a blood test for cat cancer still in development.

Fujifilm Vet Systems now has the right to develop and use a blood test for cat cancers in Japan, where it cites almost nine million cats. VolitionRx (NYSE American: VNRX) expanded its supply agreement with the Fujifilm subsidiary to cover the development and use of the Nu.Q Vet Feline Test, building on the canine test Fujifilm launched in Japan in July 2024.
Volition, based in Henderson, Nevada, expects the feline test to be the world's first simple, affordable blood-based liquid biopsy for feline cancer.
The test is still in development.
Fujifilm's dog test has a head start in Japan
Volition and Fujifilm Vet Systems first signed a supply agreement in March 2024 to sell the Nu.Q Vet Cancer Test for dogs through Fujifilm's ten central reference laboratories. In a Texas A&M study, that test detected 76% of systemic cancers in dogs at 97% specificity.
By March 6th, 2026, Fujifilm had finished validating an automated version of the canine test. Fujifilm said then that more than 1,700 Japanese veterinary hospitals had registered to use the test.
In that same March announcement, Volition's release described Fujifilm Vet Systems as having relationships with an estimated 11,000 veterinary medical facilities in Japan. By our calculation, 1,700 registered hospitals is about 15% of those 11,000 facilities.
"Since our launch of the Nu.Q Vet Canine Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians," said Junichi Makino, President and Representative Director at Fujifilm Vet Systems. He added, "Feline oncology lacks tumor biomarkers and so cancer in cats has been notoriously difficult to diagnose early."
The feline evidence so far is a lymphoma study
Volition's feline evidence is a manuscript on lymphoma, the most common cancer in cats according to the company. The manuscript, submitted for peer review in May, reports that the prototype assay detected 86% of feline lymphomas at 97% specificity.
Cameron Reynolds, President and Group Chief Executive Officer, said in Volition's November third-quarter update, "We currently anticipate publication of this study this quarter."
Volition said a peer-reviewed publication is a necessary condition to unlock a $5M milestone payment.
Volition reported third-quarter revenue of about $1.6M and cash of about $2.4M at the end of September.
Dr. Jasmine Kway, CEO of Singapore Volition, said the expansion "presents an exciting revenue opportunity for Volition." She said one in five cats will be diagnosed with cancer in their lifetimes.
Volition's mission, she said, is "to make cancer screening a routine part of every pet's annual wellness check."
Dog cancer blood tests already have several sellers
Other diagnostics companies already sell Volition's canine test. IDEXX began offering the Nu.Q Vet Cancer Test through its U.S. reference laboratories in January 2023, and Antech launched an in-clinic version on its Element i+ analyzer in the U.S. and Europe in April 2024, with results in about six minutes.
PetDx takes a different route. Its OncoK9 Screen test reads cell-free DNA by sequencing. PetDx reported in JAVMA sensitivity above 70% across seven cancer types in nearly 2,000 dogs.
OncoK9 is sold for dogs.
IDEXX has its own cancer product too. CEO Mike Erickson said Cancer Dx is "becoming a multi-cancer panel."
For Japanese clinics already registered for the dog test, the feline version would cover a second species on the same Fujifilm lab channel. Fujifilm's Makino cited almost nine million cats in Japan, while Volition's Kway cited approximately seven million pet dogs in March. For rival test makers, it adds a cat test in development to a field where the blood tests named here are sold for dogs.
Cats also keep gaining share of the exam room. CATalyst Council reported cats at 24% of U.S. companion animal clinic visits in the third quarter of 2026, up from 21% in the third quarter of 2023.
Next, Fujifilm plans a further study with veterinary oncologists in Japan, and Volition plans to finish product development and launch the test on the IDS i10.
Neither company gave a launch date.
Source: Volition via PR Newswire
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
